Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial

BACKGROUND: The PIROUETTE (PIRfenidOne in patients with heart failUre and preserved lEfT venTricular Ejection fraction) trial is designed to evaluate the efficacy and safety of the anti-fibrotic pirfenidone in patients with chronic heart failure and preserved ejection fraction (HFpEF) and myocardial...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cardiovasc Drugs Ther
Päätekijät: Lewis, Gavin A., Schelbert, Erik B., Naish, Josephine H., Bedson, Emma, Dodd, Susanna, Eccleson, Helen, Clayton, Dannii, Jimenez, Beatriz Duran, McDonagh, Theresa, Williams, Simon G., Cooper, Anne, Cunnington, Colin, Ahmed, Fozia Zahir, Viswesvaraiah, Rajavarma, Russell, Stuart, Neubauer, Stefan, Williamson, Paula R., Miller, Christopher A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2019
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6689029/
https://ncbi.nlm.nih.gov/pubmed/31069575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-019-06876-y
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia